financetom
Business
financetom
/
Business
/
AI chip firm Cerebras Systems files to withdraw its highly anticipated US listing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
AI chip firm Cerebras Systems files to withdraw its highly anticipated US listing
Oct 3, 2025 3:28 PM

(Reuters) -AI chip startup Cerebras Systems, which competes with industry leader Nvidia ( NVDA ) in the booming AI chip market, on Friday filed to withdraw its plans for an initial public offering in the United States, effective immediately.

Its withdrawal comes as U.S. IPO activity picks up in recent months, reversing an earlier slowdown caused by trade-policy uncertainty, with recent listings drawing strong investor demand.

Cerebras on Tuesday said it raised $1.1 billion in a funding round led by Fidelity Management & Research and Atreides Management, valuing the company at $8.1 billion.

"Given that Cerebras just very recently completed a sizeable fund raise, it is of no surprise that they are holding off to pursue the IPO at this time," said Josef Schuster, CEO of IPO research firm IPOX.

Last year, Cerebras filed for an initial public offering on the Nasdaq. The company's highly anticipated listing was delayed by a U.S. national security review of a $335 million investment by G42, an Abu Dhabi-based cloud computing and AI company.

"We believe this is more a company-specific strategic decision and does not tell us anything about the state of U.S. IPO sentiment, which we view as exceptionally strong," Schuster added.

Sunnyvale, California-based Cerebras Systems makes high-performance AI chips and systems designed to speed up training and running large AI models, offering faster and cheaper alternatives to traditional GPUs.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved